Article info
Public health ethics
Is there a nocebo response that results from disease awareness campaigns and advertising in Australia, and can this effect be mitigated?
- Correspondence to Mr Stuart Benson, College of Medicine and Public Health, Flinders University, Adelaide, SA 5042, Australia; bens0066{at}flinders.edu.au
Citation
Is there a nocebo response that results from disease awareness campaigns and advertising in Australia, and can this effect be mitigated?
Publication history
- Received August 4, 2017
- Revised April 14, 2018
- Accepted May 2, 2018
- First published May 15, 2018.
Online issue publication
August 22, 2018
Article Versions
- Previous version (15 May 2018).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.
Other content recommended for you
- Placebo and nocebo effects and mechanisms associated with pharmacological interventions: an umbrella review
- PO104 Placebo and nocebo responses in rls: a meta-analysis
- Placebo effects and racial and ethnic health disparities: an unjust and underexplored connection
- Placebos in chronic pain: evidence, theory, ethics, and use in clinical practice
- The nocebo effect
- Sharing online clinical notes with patients: implications for nocebo effects and health equity
- Treatment journey in rheumatoid arthritis with biosimilars: from better access to good disease control through cost savings and prevention of nocebo effects
- Unethical informed consent caused by overlooking poorly measured nocebo effects
- Recommendations for the development, implementation, and reporting of control interventions in efficacy and mechanistic trials of physical, psychological, and self-management therapies: the CoPPS Statement
- Era of biosimilars in rheumatology: reshaping the healthcare environment